Faith E Davies

发表

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma

Jack Ishak, Irina Proskorovsky, F. Davies, 2014, Health and Quality of Life Outcomes.

The CCND1 870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma

Asta Försti, Lewin Eisele, Hartmut Goldschmidt, 2013, Nature Genetics.

Guidelines for the use and interpretation of assays for monitoring autophagy

Robert Clarke, Hong Jiang, Hiroyuki Ishida, 2012 .

Genetics and Cytogenetics of Multiple Myeloma

Bart Barlogie, Rafael Fonseca, Herve Avet-Loiseau, 2004, Cancer Research.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

G. Morgan, M. Drayson, F. Davies, 2003, The New England journal of medicine.

Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma.

Cheng Li, Paola E Leone, Fiona M Ross, 2006, Blood.

Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.

Fiona M Ross, Antonino Neri, G. Morgan, 2011, Blood.

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

Gordon Cook, David A Cairns, G. Morgan, 2014, Nature Communications.

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.

S. Barrans, G. Morgan, I. Carter, 2002, Blood.

Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.

Gary Box, Mateus Crespo, Nina Tunariu, 2014, Journal of the National Cancer Institute.

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.

Jian Hou, Bart Barlogie, Michele Cavo, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

Gordon Cook, David A Cairns, Matthew Scales, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma

Pingping Qu, Bart Barlogie, Antje Hoering, 2017, Haematologica.

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

Lisa J. Murray, Sean Humphray, D. Bentley, 2013, Leukemia.